| Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo A Biscans, A Coles, R Haraszti, D Echeverria, M Hassler, M Osborn, ... Nucleic Acids Research, 2018 | 156 | 2018 |
| Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways MF Osborn, AH Coles, A Biscans, RA Haraszti, L Roux, S Davis, S Ly, ... Nucleic Acids Research, 2018 | 115 | 2018 |
| Optimized cholesterol-siRNA chemistry improves productive loading onto extracellular vesicles RA Haraszti, R Miller, MC Didiot, A Biscans, JF Alterman, MR Hassler, ... Molecular Therapy 26 (8), 1973-1982, 2018 | 86 | 2018 |
| The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo A Biscans, A Coles, D Echeverria, A Khvorova Journal of controlled release 302, 116-125, 2019 | 56 | 2019 |
| Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles A Biscans, J Caiazzi, N McHugh, V Hariharan, M Muhuri, A Khvorova Molecular Therapy 29 (4), 1382-1394, 2021 | 48 | 2021 |
| Hydrophobically modified let-7b miRNA enhances biodistribution to NSCLC and downregulates HMGA2 in vivo M Segal, A Biscans, ME Gilles, E Anastasiadou, R De Luca, J Lim, ... Molecular Therapy-Nucleic Acids 19, 267-277, 2020 | 47 | 2020 |
| The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy A Biscans, J Caiazzi, S Davis, N McHugh, J Sousa, A Khvorova Nucleic Acids Research 48 (14), 7665-7680, 2020 | 45 | 2020 |
| Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to peptide nucleic acid … BMDC Godinho, JW Gilbert, RA Haraszti, AH Coles, A Biscans, L Roux, ... nucleic acid therapeutics 27 (6), 323-334, 2017 | 45 | 2017 |
| Hydrophobicity of lipid-conjugated siRNAs predicts productive loading to small extracellular vesicles A Biscans, RA Haraszti, D Echeverria, R Miller, MC Didiot, M Nikan, ... Molecular Therapy 26 (6), 1520-1528, 2018 | 41 | 2018 |
| Synthesis and Evaluation of Parenchymal Retention and Efficacy of a Metabolically Stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA Conjugate in … M Nikan, MF Osborn, AH Coles, A Biscans, BMDC Godinho, RA Haraszti, ... Bioconjugate chemistry 28 (6), 1758-1766, 2017 | 38 | 2017 |
| Transvascular delivery of hydrophobically modified siRNAs: gene silencing in the rat brain upon disruption of the blood-brain barrier BMDC Godinho, N Henninger, J Bouley, JF Alterman, RA Haraszti, ... Molecular Therapy 26 (11), 2580-2591, 2018 | 37 | 2018 |
| Exploring the emergence of RNA nucleosides and nucleotides on the early Earth A Biscans Life 8 (4), 57, 2018 | 28 | 2018 |
| Innovative developments and emerging technologies in RNA therapeutics F Halloy, A Biscans, KE Bujold, A Debacker, AC Hill, A Lacroix, O Luige, ... RNA biology 19 (1), 313-332, 2022 | 25 | 2022 |
| Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1 SM Davis, VN Hariharan, A Lo, AA Turanov, D Echeverria, J Sousa, ... Molecular Therapy-Nucleic Acids 29, 135-149, 2022 | 25 | 2022 |
| Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity WF Lim, M Forouhan, TC Roberts, J Dabney, R Ellerington, AA Speciale, ... Science Advances 7 (34), eabi6896, 2021 | 24 | 2021 |
| RNAi-based modulation of IFN-γ signaling in skin Q Tang, J Sousa, D Echeverria, X Fan, YC Hsueh, K Afshari, N MeHugh, ... Molecular Therapy 30 (8), 2709-2721, 2022 | 19 | 2022 |
| Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo A Biscans, S Ly, N McHugh, DA Cooper, A Khvorova Journal of Controlled Release 349, 831-843, 2022 | 17 | 2022 |
| A versatile post-synthetic method on a solid support for the synthesis of RNA containing reduction-responsive modifications A Biscans, S Rouanet, JJ Vasseur, C Dupouy, F Debart Organic & Biomolecular Chemistry 14 (29), 7010-7017, 2016 | 16 | 2016 |
| Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin Q Tang, HH Fakih, M Zain UI Abideen, SR Hildebrand, K Afshari, ... Nature Communications 14 (1), 7099, 2023 | 15 | 2023 |
| Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection VN Hariharan, M Shin, CW Chang, D O’Reilly, A Biscans, K Yamada, ... Proceedings of the National Academy of Sciences 120 (11), e2219523120, 2023 | 15 | 2023 |
